Masofaniten, also known by its developmental code name EPI-7386, is an N-terminal domain antiandrogen, or antagonist of the N-terminal domain (NTD) of the androgen receptor (AR), which is under development for the treatment of prostate cancer.[1][2][3] The compound was developed as a successor of previous drugs in the EPI series such as EPI-001, ralaniten (EPI-002), and ralaniten acetate (EPI-506).[1][2][3] EPI-7386 shows 20-fold higher antiandrogenic potency than ralaniten in vitro (IC50 = 535 nM vs. 9,580 nM, respectively), as well as greater stability in human hepatocytes.[1][2][3] It was planned to enter phase I clinical trials in 2020.[3] Preliminary results of a phase I/II clinical trial were published in 2023.[4][5]
Clinical data | |
---|---|
Other names | EPI-7386 |
Routes of administration | By mouth |
Drug class | N-Terminal domain antiandrogen |
Identifiers | |
| |
CAS Number |
|
PubChem CID |
|
UNII |
|
ChEMBL |
|
Chemical and physical data | |
Formula | C24H24Cl2N4O4S |
Molar mass | 535.44 g·mol−1 |
3D model (JSmol) |
|
| |
|